Welcome to our dedicated page for Quantum-Si news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si stock.
Quantum-Si Incorporated develops proteomics technology for single-molecule protein sequencing and protein analysis. Its updates center on benchtop platform development, real-time kinetic-based detection, and product work around Proteus instruments, the KinetIQ Array and Platinum Pro customer use.
Recurring company news includes quarterly financial results and non-GAAP operating measures, Proteus prototype and integrated-instrument sequencing milestones, amino-acid detection coverage, customer sample testing, scientific posters and manuscripts using Quantum-Si technology, investor conference participation, and equity-inducement grants under Nasdaq rules.
Quantum-Si (NASDAQ: QSI) announced its participation in the 16th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 17, 2022, in New York. CEO Jeff Hawkins and COO Patrick Schneider will engage in a fireside chat at 3:30 pm ET, discussing advancements in the commercialization of their innovative Platinum™ protein sequencing instrument, aimed at revolutionizing proteomics. A live and archived webcast will be available in the Investors section of the Quantum-Si website.
Quantum-Si Incorporated (NASDAQ: QSI) will announce its third-quarter 2022 financial results on November 7, 2022, after market close. Management will host a conference call at 4:30 p.m. ET on the same day to discuss these results and provide a business update. Quantum-Si focuses on advancing proteomics through its innovative semiconductor chip designed for single-molecule protein sequencing, enhancing drug discovery and diagnostics beyond traditional DNA sequencing methods.
Quantum-Si, a life sciences company (NASDAQ: QSI), announced a groundbreaking development in protein sequencing technology. Published in Science, their research presents a next-generation single-molecule protein sequencing platform utilizing semiconductor chips and Time Domain Sequencing™, offering real-time amino acid insights. This innovation promises to enhance drug discovery and diagnostics, significantly impacting biomedical research. Founded by Dr. Jonathan Rothberg, Quantum-Si aims to redefine proteomics, facilitating greater understanding of proteins and their roles in health and disease.
Quantum-Si Incorporated (NASDAQ: QSI) has appointed Jeff Hawkins as its new Chief Executive Officer, effective October 10, 2022. Hawkins succeeds Dr. Jonathan Rothberg, who has been Interim CEO since the company's founding. With over 20 years in life sciences, Hawkins previously led significant growth at Illumina and Truvian Sciences. He will oversee the launch of Quantum-Si's Platinum™ instrument, the first next-generation single-molecule protein sequencing platform. This transition aims to propel the company into a new growth phase.
Quantum-Si Incorporated (Nasdaq: QSI) announced participation in the Morgan Stanley 20th Annual Global Healthcare Conference from September 12-14, 2022, in New York, NY. Patrick Schneider, President and COO, will engage in a fireside chat on September 14, 2022, at 10:35 am ET. The discussion will focus on the company's advancements toward commercialization of the Platinum™ instrument, a pioneering platform for single-molecule protein sequencing. A live and archived webcast will be available in the Investors section of Quantum-Si's website.
Quantum-Si Incorporated (Nasdaq: QSI) reported its second quarter 2022 financial results, revealing a net loss of $32.4 million, an improvement from a loss of $35.7 million in Q2 2021. Operating expenses decreased 6% to $30.2 million. Research and development costs rose to $18.5 million due to increased product development activities. Despite the challenges, the company achieved significant milestones in protein sequencing, demonstrating recognition of 15 out of 20 amino acids. Quantum-Si maintains a strong cash position of $400.7 million, enabling continued business investments.
Quantum-Si Incorporated (NASDAQ: QSI) announced participation in two investor conferences featuring President and COO Patrick Schneider. The Canaccord Genuity 42nd Annual Growth Conference is on August 10, 2022, at 8:30 am ET, and the UBS Genomics 2.0 and MedTech Innovations Summit is on August 11, 2022, at 3:00 pm PT. Discussions will focus on the company's advancements in commercializing its innovative Platinum™ instrument for single-molecule protein sequencing. Archived webcasts will be available on Quantum-Si's website.
Quantum-Si Incorporated (NASDAQ: QSI) announced it will report its financial results for Q2 2022 after market close on August 8, 2022. A conference call will be held on the same day at 4:30 p.m. ET to discuss the results and provide a business update. Quantum-Si focuses on innovative single molecule protein sequencing technologies aimed at advancing proteomics, drug discovery, and diagnostics.
Quantum-Si Incorporated, a life sciences company, announces its inclusion in the Russell 2000® Index effective June 27, 2022. This significant milestone follows its public trading anniversary and is expected to enhance stock visibility among investors. The Russell indexes serve as benchmarks for numerous investment strategies, managing about $12 trillion in assets. The company is advancing its single molecule protein sequencing technology, aiming to transform proteomics and improve drug discovery.
Quantum-Si Incorporated (NASDAQ: QSI) announced the appointment of Vikram Bajaj, Ph.D., to its Board of Directors on June 16, 2022. Dr. Bajaj, co-founder and former Chief Scientific Officer of Verily, brings extensive expertise in precision medicine and life sciences investment. His role is expected to bolster Quantum-Si's commercialization strategy for its next-generation protein sequencing system, which aims to revolutionize proteomics. CEO Jonathan Rothberg highlighted Bajaj's significant experience as critical to advancing the company's ambitious goals.